On May 2, 2022 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will present new preclinical data on PH-894 for use in adoptive cell therapy (ACT) at the American Society for Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 25th Annual Meeting, which is being held May 16-19, 2022 in-person in Washington, D.C. and virtually (Press release, Phio Pharmaceuticals, MAY 2, 2022, View Source [SID1234613337]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Logo – View Source

Poster Details are as follows:

Title:

Self-Delivering RNAi Targeting BRD4 (PH-894) Improves the
Phenotype of HER2-CAR-T Cells During Expansion

Author:

Benjamin Cuiffo, et al.

Abstract Number:

222

Session:

Oligonucleotide Therapeutics I

Session Date and Time:

Monday, May 16, 2022 5:30 PM – 6:30 PM EDT

Location:

Walter E. Washington Convention Center, Hall D